<i>In vitro</i> and <i>in vivo</i> identification of clinically approved drugs that modify <i> <scp>ACE</scp> 2 </i> expression
The COVID-19 pandemic caused by SARS-CoV-2 has is a global health challenge. Angiotensin-converting enzyme 2 (ACE2) is the host receptor for SARS-CoV-2 entry. Recent studies have suggested that patients with hypertension and diabetes treated with ACE inhibitors (ACEIs) or angiotensin receptor blocke...
Saved in:
Main Authors: | , , , , , |
---|---|
格式: | Artigo |
語言: | 英语 |
出版: |
2020
|
在線閱讀: | https://doi.org/10.15252/msb.20209628 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|